Page 1,564«..1020..1,5631,5641,5651,566..1,5701,580..»

When states have strong guns laws, they also have fewer fatal police shootings – Los Angeles Times

Posted: May 19, 2017 at 5:46 am

Fatal shootings of civilians by police officers are less common in states with stricter gun laws than they are in states that take a more relaxed approach to regulating the sale, storage and use of firearms, new research says.

A study published Thursday in the American Journal of Public Health has found that fatal police shootings were about half as common in states whose gun laws place them in the top 25% of stringency than they were in states where such restrictions ranked in the bottom 25%.

The new findings draw from an analysis of 1,835 firearms-related deaths involving a police officer in the United States all such fatalities reported in the 22 months following Jan. 1, 2015. It found that, of 42 laws enacted by states, the ones most strongly linked to lower fatal police shootings were those that aimed to strengthen background checks, to promote safe firearm storage, and to reduce gun trafcking.

We suspect that because these states have more robust gun laws, theyre better able to keep guns out of the hands of the wrong people, said the studys lead author, University of Indianapolis psychology professor Aaron Kivisto. The likely result, he suggested, is that police in such states are just less likely to encounter people in circumstances where they shouldnt have a gun.

The association held up even after researchers accounted for state differences in the density and demographics of its citizens.

The study results add to a broad pattern of findings about states rates of gun ownership, which largely rise and fall along with gun-related suicides, accidental firearm injuries and domestic violence deaths.

New Mexico, Wyoming, Alaska, Oklahoma and Arizona led the country in rates of fatal police shootings, which were calculated as the number of such deaths per 1 million state residents. All but Oklahoma had among the most relaxed gun laws on their books.

Rhode Island, New York, Connecticut, Massachusetts and Illinois were among the states with the lowest rates of officer-involved fatal shootings. All had gun laws that placed them among the nations most restrictive states.

But not all states fit the pattern. California was especially unusual, Kivisto said: Though the state claimed the No. 1 position for stringency of gun laws, its rate of fatal police shootings during the study period was much higher than the national average. In fact, the rate of officer-involved gun deaths in California fell between those of South Dakota and Alabama, two states with some of the scantest restrictions on the sale, ownership and use of guns.

Kivisto suggested that for some states, including California, statutory efforts to staunch the supply of guns on the streets were likely being undermined by gun trafficking from neighboring states. Arizona and Nevada have gun laws that are among the nations least restrictive (as well as rates of fatal police shooting that are well above the norm).

A state can have the strongest gun laws possible, but it cant stop gun from flowing across state boundaries, Kivisto said. One of strongest arguments for federal gun laws would be that some uniformity may be needed to stop guns flowing in from other states.

Other states bucked the national pattern by maintaining both few gun restrictions and low rates of officer-involved fatal shootings. This group included Maine, North Dakota, New Hampshire and Indiana.

Kivisto and his co-authors did not rely on Justice Department statistics of police-related shootings, since states are not required to report those and dont necessarily do so routinely. Instead, the researchers relied on a running tally of officer-involved fatalities maintained by the British newspaper The Guardian, a source that is considered comprehensive.

In addition to verifying and chronicling the time, location and circumstances of the shootings, The Guardians database, called The Counted, also documents the victims gender, race or ethnicity, whether he (96% of all victims during the study period were male) was armed, and by what mechanism the victim was killed (for instance, by taser, by firearm or struck by a car).

Of 2,021 fatalities during the 22-month study period, 1,835 were killed with a police officers gun. And in 53% of those cases, the person killed was also armed with a gun. One in 10 were thought to be entirely unarmed at the time of the fatal shooting. Individuals from racial or ethnic minority groups made up slightly more than one-third of all victims.

melissa.healy@latimes.com

@LATMelissaHealy

ALSO

Scientists get closer to making personalized blood cells by using patients' own stem cells

Experts measure food waste not in dollars or tons, but by calories, vitamins and minerals

Rising sea levels could mean twice as much flood risk in Los Angeles and other coastal cities

Go here to see the original:
When states have strong guns laws, they also have fewer fatal police shootings - Los Angeles Times

Posted in Alabama Stem Cells | Comments Off on When states have strong guns laws, they also have fewer fatal police shootings – Los Angeles Times

China agrees to review US biotechnology applications – Chemical & Engineering News

Posted: May 19, 2017 at 5:46 am

China will evaluate eight pending U.S. agricultural biotechnology product applications by the end of May, potentially opening the door for sales by Dow AgroSciences, DuPont Pioneer, Monsanto, and Syngenta.

China agreed to conduct the evaluations as part of an agreement unveiled by the White House on May 12. The two countries reached the trade deal after a meeting in April between U.S. President Donald J. Trump and Chinese President Xi Jinping.

U.S. officials have prodded China for years to speed up its lengthy process for deciding whether to approve the import of new genetically modified (GM) crops. It typically takes six years to win Chinese clearance of a GM variety, twice as long as other major nations take.

Under the new deal, Chinas National Biosafety Committee will meet by the end of May to assess the safety of eight products made by four major U.S. agrochemical companies.

Dow AgroSciences is seeking approval for its corn and soybean seeds, while Syngenta and DuPont Pioneer have each applied to sell a GM corn variety in China. Monsanto makes four of the products pending approval, including herbicide-tolerant corn, soybeans, and two alfalfa varieties that have been under review for nearly six years.

The Biotechnology Innovation Organization (BIO), an industry trade group, wants to make sure China lives up to its commitment.

The ultimate test of success will be for China to follow its process and quickly approve the eight pending biotechnology applications and establish a synchronized, timely, and predictable process going forward, says Joseph Damond, senior vice president for international affairs at BIO.

View post:
China agrees to review US biotechnology applications - Chemical & Engineering News

Posted in Biotechnology | Comments Off on China agrees to review US biotechnology applications – Chemical & Engineering News

Bucks commissioners OK state award of $2 million for Pa. Biotechnology Center expansion – The Intelligencer

Posted: May 19, 2017 at 5:46 am

The Bucks County commissioners unanimously approved a $2 million state grant that will aid the expansion of the Pennsylvania Biotechnology Center in Buckingham.

With their vote Wednesday, the commissioners accepted the agreement between the biotechnology center and the state, and agreed to act as the facilitator for the Redevelopment Assistance Capital Program (RACP).

"Every entity that applies for the RACP grant has to have a cooperation agreement with one of the governments to move forward," said Lynn Bush, executive director of the Bucks County Planning Commission. "We are basically the go-between for the company and the state agency."

Plans have been in motion for years to add more laboratory and office space to the Biotechnology Center. The state grant and a $4.6 million federal grant will contribute to the overall costs of the project, estimated between $12 million and $13 million. The remainder willbe financed with a conventional loan awarded by Univest Bank.

"We're thrilled to continue our partnership with the biotechnology center and allow them the opportunity to grow and expand in that area," said Bucks County Commissioner Robert Loughery. "The center has become a real success story for the county and the region."

A groundbreaking ceremony for the expansion was held in April, but actual construction has yet to begin. Before work could begin in earnest, Bush said Thursday afternoon the plans need to go before the Buckingham Board of Supervisors for final land development approval.

The Biotechnology Center is credited with contributing approximately $1.8 billion to the local economy and supporting more than 700 jobs since its creation in 2007. A partnership with the Hepatitis B Foundation and Delaware Valley University started the initiative, but disagreements on the center's management ended the relationship.

The Hepatitis B Foundation bought out the university's interests in the center for $2 million in October, ending the disagreement and restarting the stalled expansion plans.

Link:
Bucks commissioners OK state award of $2 million for Pa. Biotechnology Center expansion - The Intelligencer

Posted in Biotechnology | Comments Off on Bucks commissioners OK state award of $2 million for Pa. Biotechnology Center expansion – The Intelligencer

Digging Up the Facts on Puma Biotechnology, Inc. (PBYI) – StockNewsJournal

Posted: May 19, 2017 at 5:46 am


FinancialsTrend
Digging Up the Facts on Puma Biotechnology, Inc. (PBYI)
StockNewsJournal
Puma Biotechnology, Inc. (PBYI) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $36.25, up from yesterday's close by 13.46%. Given the stock's recent action ...
Reasons to Add Puma Biotechnology (PBYI) to Portfolio NowNasdaq
Does Puma Biotechnology Inc. (NASDAQ:PBYI) deserve your investment?FinancialsTrend
Puma Biotechnology Inc (PBYI) Soars 6.21% on May 18Equities.com
TopChronicle -BBNS -PharmiWeb.com (press release)
all 28 news articles »

See the article here:
Digging Up the Facts on Puma Biotechnology, Inc. (PBYI) - StockNewsJournal

Posted in Biotechnology | Comments Off on Digging Up the Facts on Puma Biotechnology, Inc. (PBYI) – StockNewsJournal

Puma Biotechnology, Inc. (PBYI): Some of the key technical areas – USA Commerce Daily

Posted: May 19, 2017 at 5:46 am


USA Commerce Daily
Puma Biotechnology, Inc. (PBYI): Some of the key technical areas
USA Commerce Daily
With all other things going on, Puma Biotechnology, Inc. (NASDAQ:PBYI) has been on a free fall declining -4.23 percent in just three months. It looks like traders are not happy with the stock. On the other side, analysts now consider Puma ...

and more »

See original here:
Puma Biotechnology, Inc. (PBYI): Some of the key technical areas - USA Commerce Daily

Posted in Biotechnology | Comments Off on Puma Biotechnology, Inc. (PBYI): Some of the key technical areas – USA Commerce Daily

Stem Cell International – Stem Cell Therapy In Toledo, OH …

Posted: May 19, 2017 at 5:45 am

WARNING

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close [x]

THIS ---->https://stemcellinternationalorg.imatrixbase.com/

OUR MISSION

The affiliates of the Stem Cell International are devoted to advancing access and quality care in the area of adult stem cell regenerative medicine in order to help people suffering from a variety of inflammatory and degenerative conditions.

Toledo | Stem Cell International | 419-214-1860

**SCI (Stem Cell International) does not claim to cure any disease or condition stated above. Note: We as a company have invested in state of the art equipment designed to uitilize a combination of growth factors (i.e. adult stem/Stromal cells), allowing us to harness your body's NATURAL restorative properties. We have had training from world renowned specialists on reintroducing your own stem/Stromal cells to activate your body's amazing ability to regenerate, promoting wellness through Regenerative Medicine.

Specific Conditions

What can we help you find?

Original post:
Stem Cell International - Stem Cell Therapy In Toledo, OH ...

Posted in Cell Therapy | Comments Off on Stem Cell International – Stem Cell Therapy In Toledo, OH …

Mouse study looks at safety of stem cell therapy for early menopause – Medical Xpress

Posted: May 19, 2017 at 5:45 am

May 18, 2017

Now that we know that egg-making stem cells exist in adult rodents and humans and that these cells can be transplanted into mice with premature ovarian failure to produce offspring, the next question is to assess whether the offspring from the egg-making stem cells of a single adult mouse are biologically normal compared to natural births. On May 18 in the journal Molecular Therapy, researchers in China show that female mice with early menopause that receive egg-making stem cells from another mouse are capable of producing healthy pups 2 months later with no observable genetic malfunctions.

"One of our aims is to cure the disease of premature ovarian failure using female germline stem cells," says senior author Ji Wu, a reproductive biologist at Shanghai Jiao Tong University. "Before this treatment can be applied to humans, we need to know the mechanism of female germline stem cell development and safety after transplantation of single mouse female germline stem cells."

Premature ovarian failure, also called early menopause, is the loss of normal ovarian function, and thereby the release of eggs, before the age of 40. The condition is rare, affecting 200,000 women in the United States per year, and is incurable, although it can be treated with hormone supplements. Multiple groups are now looking at whether stimulating tissue regeneration or using stem cell transplants could help.

In the Molecular Therapy study, Wu and her colleagues isolated and characterized female germline stem cells from a single transgenic mouse with cells that show green fluorescence when activated by a blue laser. This allowed the researchers to observe and analyze the development of the transplanted stem cells, which were introduced to the ovaries of other mice using a fine glass needle.

Wu and colleagues found that the transplanted egg-producing stem cells exhibited a homing ability and began to differentiate into early-stage oocytes when they reached the edge of the ovary. The oocytes spent a few weeks maturing and yielded offspring within 2 months. The researchers then demonstrated that the developmental mechanisms of eggs derived from transplanted germline stem cells were similar to that of normal eggs.

"The results are exciting because it's not easy to get offspring from female germline stem cells derived from a single mouse," Wu says.

Wu's lab is also working to establish female egg-producing stem cell lines from scarce ovarian tissues derived from follicular aspiratesthe leftover cells gathered when a clinician searches a patient for oocytesthat are produced and discarded in in vitro fertilization centers worldwide. These aspirates can yield stem cells that differentiate into eggs in the lab, with the potential to be transplanted. The study not only provides a new approach to obtain human female germline stem cells for medical treatment, but also opens several avenues to investigate human oogenesis in vitro.

Explore further: Making sperm from stem cells in a dish

More information: Molecular Therapy, Wu et al.: "Tracing and characterizing the development of transplanted female germline stem cells in vivo" http://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(17)30180-6 , DOI: 10.1016/j.ymthe.2017.04.019

Journal reference: Molecular Therapy

Provided by: Cell Press

In a turnabout, a biochemical self-destruct trigger found in many other types of cells appears to guard the lives of brain cells during an infection with West Nile virus.

Researchers have discovered that protection from the most severe form of malaria is linked with natural variation in human red blood cell genes. A study from the Wellcome Trust Sanger Institute, the Wellcome Trust Centre ...

A protein called ZFP568 regulates an important fetal growth hormone called insulin-like growth factor 2 (Igf2), according to a mouse study led by researchers at the National Institutes of Health. The study is one of the first ...

Now that we know that egg-making stem cells exist in adult rodents and humans and that these cells can be transplanted into mice with premature ovarian failure to produce offspring, the next question is to assess whether ...

It's a fat-burning secret anyone interested in bone health should know. For the first time, UNC School of Medicine researchers show that exercising burns the fat found within bone marrow and offers evidence that this process ...

A Cedars-Sinai-led team of investigators has successfully repaired severe limb fractures in laboratory animals with an innovative technique that cues bone to regrow its own tissue. If found to be safe and effective in humans, ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the rest here:
Mouse study looks at safety of stem cell therapy for early menopause - Medical Xpress

Posted in Cell Therapy | Comments Off on Mouse study looks at safety of stem cell therapy for early menopause – Medical Xpress

Anti-CD19 CAR-T cell therapy with defined T-cell subsets for ibrutinib-refractory CLL presentation at iwCLL 2017 – Lymphoma Hub

Posted: May 19, 2017 at 5:45 am

During iwCLL, on 15th May 2017, the Additional Therapies for the Relapsed/Refractory CLL Patient session took place and was co-chaired by Michael Keating (MD Anderson Cancer Center) and Jacqueline Barrientos (The Feinstein Institute for Medical Research).

Anti-CD19 CAR-T Cell Therapy With Defined T-Cell Subsets for Ibrutinib-Refractory CLL was a presentation given during this session by David G. Maloney, MD, PhD, from the Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Maloney began by explaining that CAR-T cells produced from distinct T-cell subsets differ in potency. NSG mice bearing Raji tumors (0.5x106 tumor cell inoculation; day 0) were treated with human CAR-T cells manufactured from distinct T-cell subsets (on day 7). CAR-T cells produced from CD8+ TCM cells were highly potent (Sommermeyer et al. 2015).

Engineering selected T-cell subsets could enhance potency and allow delivery of the same cell product in all patients, potentially providing more uniform data on dose response and toxicity.

Pre-clinical studies have established that a defined composition of CD8+ TCM derived and CD4+ derived CAR T-cells provides optimal potency.

The talk then focused on the outline of the phase I/II study of JCAR014 in adult B-cell ALL, NHL, and CLL patients (NCT01865617).

As of 9/1/16, 136 patients had been treated: ALL = 48, NHL = 64, and CLL = 24.

Dose Level

Cells/kg

1

2x105 EGFRt+

2

2x106 EGFRt+

3

2x107 EGFRt+

Lymphodepletion and JCAR014 immunotherapy in high-risk CLL patients:

Treatment

N=24

Lymphodepleting chemotherapy

Cyclophosphamide/fludarabine (Cy/Flu)

21 (87%)

Non-Cy/Flu

3 (13%)

CAR-T cell manufacturing

CD8+ central memory and CD4+

7 (29%)

CD8+ all subsets and CD4+

17 (71%)

CD19 CAR-T cell dose level

DL1 (2x105 EGFRt+ cells/kg)

4 (17%)

DL2 (2x106 EGFRt+ cells/kg)

19 (79%)

DL3 (2x107 EGFRt+ cells/kg)

1 (4%)

Cycles

Single cycle

18 (75%)

Outpatient lymphodepletion and CAR-T cells

18 (75%)

Second cycle for residual disease or relapse

6 (25%)

Maloney then asked can IGH sequencing of the marrow at 4 weeks after JCAR014 identify patients with better outcomes?

Additionally, higher JCAR014 counts in the blood after infusion were associated with better bone marrow response in high-risk CLL. Patients with a higher peak CD3+/EGFRt+ CAR-T cell count in the blood had a reduced hazard of progression or death (HR, 0.56; 95% CI, 0.340.93; P = 0.025).

Maloney concluded that in high-risk CLL patients CD19 CAR-T cells of defined composition (JCAR014) can be administered with an acceptable early toxicity profile. JCAR014 and Cy/Flu lymphodepletion shows a high-level or anti-tumor activity as measured by:

Deep marrow clearance by IGHseq after JCAR014 provides early signs of durable responses with 100% PFS and OS.

Lastly, Maloney presented evidence that ROR1 presents as a novel target for CAR-T cell therapy for CLL, MCL, and solid tumors as it is highly expressed on the surface of malignant B-cells:

Go here to see the original:
Anti-CD19 CAR-T cell therapy with defined T-cell subsets for ibrutinib-refractory CLL presentation at iwCLL 2017 - Lymphoma Hub

Posted in Cell Therapy | Comments Off on Anti-CD19 CAR-T cell therapy with defined T-cell subsets for ibrutinib-refractory CLL presentation at iwCLL 2017 – Lymphoma Hub

Bethel kids to walk to cure diabetes – NewsTimes – Danbury News Times

Posted: May 19, 2017 at 5:44 am

Photo: Carol Kaliff / Carol Kaliff

File photo of Huckleberry Hill Elementary School in Brookfields JDRF Kids Walk for Diabetes in April 2014.

File photo of Huckleberry Hill Elementary School in Brookfields JDRF Kids Walk for Diabetes in April 2014.

Bethel kids to walk to cure diabetes

BETHEL Students will walk to raise awareness for diabetes this Saturday.

Bethel High School is hosting its first JDRF Kids Walk to Cure Diabetes to help kids and families affected by type 1 diabetes. Registration begins at 10:30 a.m., with the walk and activities running from 11 a.m. to noon at the high school track.

The Juvenile Diabetes Research Foundation (JDRF) is the leading global organization funding type 1 diabetes research. More than 15,000 children in the United States are diagnosed with type 1 diabetes each year, according to the organization.

As of Thursday afternoon, the school had raised $480, just under half of its $1,000 goal. To donate or participate, visit the teams website at http://www2.jdrf.org/site/TR?team_id=234353&fr_id=6580&pg=team. Donations can also be brought to the walk.

For questions, contact Amy Gusitsch at agusitsch@gmail.com

More here:
Bethel kids to walk to cure diabetes - NewsTimes - Danbury News Times

Posted in Diabetes | Comments Off on Bethel kids to walk to cure diabetes – NewsTimes – Danbury News Times

Journal flags two more papers by diabetes researcher who sued to stop retractions (and now has 12) – Retraction Watch (blog)

Posted: May 19, 2017 at 5:44 am

A diabetes journal has issued two notices of concern for papers co-authored by a researcher who took another publisher to court after it did the same thing but ultimately lost.

The notices are for two papers co-authored by Mario Saad who, after losing his legal battle with the American Diabetes Association, has since accumulated 12 retractions. Both notices from the journal Diabetologia, published by Springer and the the European Association for the Study of Diabetes (EASD) say they have alerted Saad to their concerns about some of the images in the papers, and the university where he is based was asked to investigate more than one year ago. Since the journal has not yet received any information from the University of Campinas in Brazil, however, it decided to issue expressions of concern for the two papers.

Heres the text of the first notice:

On the basis of the recommendation of the EASDs Scientific Integrity Panel, the Editor-in-Chief is issuing this expression of concern to alert readers to questions about the reliability of some of the data in the article cited above.

In particular it appears that the immunoblots for total IKK in Fig. 4g and k of this paper may have been duplicated.

In line with guidelines issued by the Committee on Publication Ethics (COPE), the journal has informed the corresponding author, Mario Saad, of this concern. The authors response was considered unsatisfactory and the low resolution of the images provided to us prevented further analysis to conclusively confirm or refute this possible duplication. The University of Campinas (So Paulo, Brazil) was asked, in March 2016, to undertake an institutional investigation. As no results from this investigation have been forthcoming this expression of concern is being issued to alert readers to exercise caution when interpreting the content and conclusions of this article. This expression of concern will remain in place until such a time as further evidence is available.

Modulation of gut microbiota by antibiotics improves insulin signalling in high-fat fed mice has been cited 88 times since it was published in 2012, according toClarivate Analytics Web of Science, formerly part of Thomson Reuters.

Heres the text of the second notice:

On the basis of the recommendation of the EASDs Scientific Integrity Panel, the Editor-in-Chief is issuing this expression of concern to alert readers to questions about the reliability of some of the data in the article cited above.

In particular, it appears that the bands for -tubulin in Fig. 4b are the same as the first three bands for total p70S6K in Fig. 6k in Ropelle ER et al (2008) (A central role for neuronal AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) in high-protein diet-induced weight loss. Diabetes 57(3): 594605. DOI:10.2337/db07-0573).

The journal has been unable to obtain the high resolution image used in Ropelle et al from the corresponding author, Dr Carvalheira, and the editorial office of Diabetes no longer had a copy of this image. It has therefore not been possible to use image forensics to conclusively confirm or refute this concern.

In line with guidelines issued by the Committee on Publication Ethics (COPE), the journal has informed the corresponding author, Mario Saad, of this concern. The University of Campinas (So Paulo, Brazil) was asked, in March 2016, to undertake an institutional investigation. As no results from this investigation have been forthcoming this expression of concern is being issued to alert readers to exercise caution when interpreting the content and conclusions of this article. This expression of concern will remain in place until such a time as further evidence is available.

Aspirin attenuates insulin resistance in muscle of diet-induced obese rats by inhibiting inducible nitric oxide synthase production and S-nitrosylation of IR/IRS-1 and Akt has been cited 28 times since it was published in 2009.

The Diabetes paper referenced in the EOC was retracted earlier this year.

We contacted Saad; he acknowledged our email, but did not respond to our questions.

This isnt the first publisher to question the University of Campinass actions regarding Saad as part of his lawsuit against the American Diabetes Association, it was revealed that the ADA askedthe school to reinvestigate fourarticles that the university had concluded were healthy, and refused to accept any papers from itsfaculty until the issues were resolved. The publisher eventually retracted the papers earning it the first-ever Doing The Right Thing Award from our co-founders.

Like Retraction Watch? Consider making atax-deductible contribution to support our growth. You can also follow uson Twitter, like uson Facebook, add us to yourRSS reader, sign up on ourhomepagefor an email every time theres a new post, or subscribe to ourdaily digest. Clickhere to review our Comments Policy. For a sneak peek at what were working on,click here.

Original post:
Journal flags two more papers by diabetes researcher who sued to stop retractions (and now has 12) - Retraction Watch (blog)

Posted in Diabetes | Comments Off on Journal flags two more papers by diabetes researcher who sued to stop retractions (and now has 12) – Retraction Watch (blog)

Page 1,564«..1020..1,5631,5641,5651,566..1,5701,580..»